Antibody Screening Platform

E. coli display is a prokaryotic surface display system. Antibodies can be displayed on the outer membrane or periplasm for antigen binding. Nanobodies fit this system well due to their simple structure. It has a library capacity up to 1E10. With fast growth and short cycles, it allows upstream affinity enrichment to improve specificity. NabLife’s NabLib® provides E. coli display-based antibody discovery for drug development.

Phage display, a 60-year-old technology for antibody screening, expresses antibodies on phage surface proteins such as pIII and pVIII. pVIII is most widely used with about 3,000 copies to boost signals. It offers a large library capacity of 1E10–1E11. Using E. coli expression, it features simple operation and short cycles. NabLife’s NabLib® platform provides phage display-based antibody discovery and engineering for drug development.

The mammalian cell display technology is different from other types of display technologies such as phage or yeast display. It is an advanced platform designed to optimize the drugability of therapeutic antibodies. The mammalian cells in the petri dish share many common characteristics with human cells in clinical trials and cells used for antibody industrial production. This technology is a cutting-edge tool for antibody engineering such as affinity maturation and humanization.